Paula Green Sells 1,137 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST) SVP Paula Green sold 1,137 shares of the company’s stock in a transaction dated Monday, August 5th. The stock was sold at an average price of $39.93, for a total value of $45,400.41. Following the sale, the senior vice president now owns 88,837 shares in the company, valued at approximately $3,547,261.41. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Paula Green also recently made the following trade(s):

• On Tuesday, July 2nd, Paula Green sold 322 shares of Twist Bioscience stock. The stock was sold at an average price of $48.00, for a total value of $15,456.00.
• On Thursday, June 20th, Paula Green sold 297 shares of Twist Bioscience stock. The shares were sold at an average price of $49.41, for a total value of $14,674.77.
• On Thursday, June 6th, Paula Green sold 918 shares of Twist Bioscience stock. The stock was sold at an average price of $51.33, for a total transaction of $47,120.94.

Twist Bioscience Price Performance

TWST traded down $1.45 during trading on Friday, hitting $43.97. The stock had a trading volume of 944,659 shares, compared to its average volume of 1,050,882. The company has a 50 day moving average price of $50.93 and a 200-day moving average price of $41.70. Twist Bioscience Co. has a one year low of $14.42 and a one year high of $60.90. The firm has a market cap of $2.58 billion, a price-to-earnings ratio of -13.09 and a beta of 1.80.

Twist Bioscience (NASDAQ:TWST) last announced its earnings results on Friday, August 2nd. The company reported ($1.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.71). Twist Bioscience had a negative net margin of 74.63% and a negative return on equity of 32.17%. The business had revenue of $81.50 million during the quarter, compared to the consensus estimate of $77.40 million. During the same period in the previous year, the firm posted ($1.01) EPS. The company’s revenue was up 27.7% compared to the same quarter last year. As a group, sell-side analysts predict that Twist Bioscience Co. will post -3.13 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the stock. Guggenheim began coverage on shares of Twist Bioscience in a research report on Tuesday, June 4th. They issued a “buy” rating and a $53.00 price objective for the company. Scotiabank boosted their price target on Twist Bioscience from $43.00 to $48.00 and gave the stock a “sector outperform” rating in a research report on Monday, May 6th. The Goldman Sachs Group raised their price objective on Twist Bioscience from $45.00 to $55.00 and gave the company a “buy” rating in a research report on Tuesday, July 9th. JPMorgan Chase & Co. lifted their target price on Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a research note on Monday, August 5th. Finally, Evercore ISI raised their price target on Twist Bioscience from $46.00 to $50.00 and gave the company an “outperform” rating in a report on Friday, May 3rd. One investment analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Twist Bioscience currently has an average rating of “Moderate Buy” and a consensus target price of $48.22.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. International Assets Investment Management LLC increased its stake in Twist Bioscience by 3,519.8% during the 4th quarter. International Assets Investment Management LLC now owns 4,018 shares of the company’s stock worth $148,000 after acquiring an additional 3,907 shares during the period. Sumitomo Mitsui Trust Holdings Inc. raised its stake in Twist Bioscience by 2.9% in the fourth quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 3,583,443 shares of the company’s stock valued at $132,086,000 after purchasing an additional 99,511 shares in the last quarter. Knights of Columbus Asset Advisors LLC bought a new stake in Twist Bioscience during the fourth quarter worth about $2,296,000. New York State Common Retirement Fund grew its stake in Twist Bioscience by 5.0% during the fourth quarter. New York State Common Retirement Fund now owns 370,849 shares of the company’s stock worth $13,669,000 after buying an additional 17,715 shares in the last quarter. Finally, Victory Capital Management Inc. bought a new position in Twist Bioscience in the 4th quarter valued at about $274,000.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.